Allogenic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with or without Consolidation Chemotherapy

Biology of Blood and Marrow Transplantation(2014)

Cited 0|Views4
No score
Abstract
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a highly effective post- remission treatment for patients with AML in first complete remission. The role of post-remission consolidation chemotherapy with allo-HSCT remains controversial. This study was performed to evaluate the post-remission chemotherapy efficacy before Allo-HSCT. The study included 66 acute leukemia (AML) patients who received induction regimen containing cytarabine given for 7 days and idarubicin (7+3) given for 3 days from April 2008 to July 2013. Thirty -two of patients received only induction therapy (group A) and 34 patients (group B) received induction and post-remission chemotherapy containing 5 days cytarabine and 2 days idarubicin (5+2). The conditioning regimen for transplantation was busulfan and cyclophosphsmide. Graft-versus-host disease (GvHD) prophylaxis regimen consisted of methotraxate and cyclosporin. The median follow-up was 20 (21 in group A and 19.5 in group B) months. The median time to neutrophil recovery was 12 (range: 9 to 50) and 14 (range: 10 to 27) days in groups A and B, respectively (p=0.07). The median time to platelet recovery was 15 (9 to 47) days in group A and 16 (9 to 54) days in group B (p=0.54). Acute GvHD occurred in 18 patients (6 in grade I, 8 in grade II, and 4 in grade III) in group A and 20 patients (5 grade I, 9 grade II, 6 grade III, and 1 in grade IV) in group B (56.2% vs. 58.8%; p=0.833). Eight patients experienced relapses (7 in group A and 1 in group B). Twenty-one patients (9 in group A and 12 in group B) expired. The most common causes of death were GvHD (10), relapse (5) and infection (4). Two-year leukemia-free survival (DFS) was 65.9% (SE: 9.5%) and 66.4% (SE: 8.3%) in groups A and B, respectively (p=0.547). The study indicated that there were no differences in allo-HSCT outcomes between patients with or without consolidation chemotherapy. More cases and longer time are required to confirm the preliminary data.
More
Translated text
Key words
acute myeloid leukemia,consolidation chemotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined